Abstract:The bioavailability of sublingual form of paclitaxel, developed in the pharmacology laboratory of pharmaceutical company - Legion "Provisus" is studied. Sublingual form of paclitaxel is an alcoholic solution of paclitaxel (1 mg/ml) with penetrator - dimethyl sulfoxide (DMSO) addition. Experiments were performed on 180 white mongrel male mice each of 25-30 g. The animals were divided into three groups. The first group served for control. 10 mg/kg of taxol was injected (once) in the lateral tail vein of the first group animals. A solution was prepared by diluting taxol with physiological sodium chloride solution until to a final concentration of paclitaxel to 1 mg/ml. The dose of 10 mg/kg (single dose) was applied under the tongue of the second group animals. Paclitaxel (substance) was extracted with dichloromethane - Taxol (by liquid-liquid extraction) for the manufacturing of a sublingual form. Unlike the second group, the third group animals took the same dose of sublingual form of paclitaxel orally (by gavage). The concentration of paclitaxel in plasma was studied by reversed-phase HPLC with spectrophotometric detection at λ = 227 nm by Woo JS et al. (2003) method. Bioavailability was determined by comparing the concentration of paclitaxel in blood after sublingual and intravenous use of Taxol (as an area under the curve of concentration versus time). It is established that the bioavailability of sublingual forms of paclitaxel was 42.4%, Cmax = 615 ± 73 ng × ml(-1) and tmax = 30-35 min. The value of the initial volume of distribution of paclitaxel (Vd = 3,14 ± 0,85 l × kg(-1)) also shows its intensive penetration to the organs and tissues. The half-life of the drug on the terminal segment of concentration-time curve was averaged 1,06 ± 0,21 h. The results create the preconditions for further preclinical study of sublingual form of paclitaxel, as the bioavailability of paclitaxel after sublingual application allows to have a systemic effect on the tumor process.

[Studies on Hypersensitivity and Pharmacokinetics of Paclitaxel Microemulsion].

An Alternative Paclitaxel Self-Emulsifying Microemulsion Formulation: Preparation, Pharmacokinetic Profile, and Hypersensitivity Evaluation.

An alternative paclitaxel self-emulsifying microemulsion formulation: Preparation, pharmacokinetic profile, and evaluation

Preparation of Paclitaxel Self-Emulsification Microemulison and Its Pharmacokinetics in Rats

Quantification of paclitaxel in rat plasma by LC-MS/MS and pharmacokinetics of paclitaxel thermosensi-tive liposomes in rats

Study on Pharmacokinetics of Paclitaxel Liposome in rats

ANovel Paclitaxel Microemulsion Containing a Reduced Amount of Cremophor EL : Pharmacokinetics , Biodistribution , and InVivo Antitumor Efficacy and Safety

Pharmacokinetics of Paclitaxel Nanoliposome in Rats by LC-MS/MS

Preparation and Pharmacokinetics of Paclitaxel Nanometric Liposomes in Rats

Pharmacokinetics of Paclitaxel Lyophilized Injection in Rat

Pharmacokinetics research on paclitaxel nano-liposomes in rats

Comparison of pharmacokinetics between paclitaxel emulsion for injection and paclitaxel injection in beagles

Preparation and Quality Evaluation of Paclitaxel Microemulsion by Film Dispersion Method

Preparation and tissues distribution study of paclitaxel nanometric liposomes in mice

[Study of bioavailability of paclitaxel after sublingual administration].

Biodistribution and biological evaluation of paclitaxel polymer micelles

A Study on Pharmacokinetics of Compound Capsule of Paclitaxel in Rats

Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion.

In Vitro and in Vivo Studies on Plasma-to-blood Ratio of Paclitaxel in Human, Rabbit and Rat Blood Fractions.

Preparation and Characterization of Paclitaxel Nanosuspension Using Novel Emulsification Method by Combining High Speed Homogenizer and High Pressure Homogenization

Preliminary in vivo studies of a new lecithin-based formulation of paclitaxel